Thyrocare Technologies Limited had earlier announced that the company has appointed Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the company and that he would be joining in the month of May 2022.
Mr. Rahul Guha has taken charge as the Managing Director & Chief Executive Officer with effect from Wednesday, May 04, 2022.
Mr. Rahul Guha will also function as the Managing Director & CEO of Nueclear Healthcare Limited, the wholly owned subsidiary.
Mr. Dhannil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company.
Shares of Thyrocare Technologies Limited was last trading in BSE at Rs. 747.50 as compared to the previous close of Rs. 771.60. The total number of shares traded during the day was 11644 in over 1622 trades.
The stock hit an intraday high of Rs. 777.00 and intraday low of 743.00. The net turnover during the day was Rs. 8802927.00.